Report Highlights
-
The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011.
-
Ophthalmic pharmaceuticals dominated the market throughout the forecast period. In 2006 pharmaceuticals comprised 46.6% of the market and, growing at an AAGR of 6.9%, will be worth more than $6.2 billion and maintain more than 45% of the market in 2011.
-
Contact lenses include both functional and cosmetic lenses. Contact lenses generate approximately $1.9 billion in revenues annually in the United States, accounting for a near 20% of the market.
INTRODUCTION
The aging of the population in the United States will result in a two-fold increase in the 65 and over population by 2030, a population that accounts for the highest incidence and prevalence of eye conditions and diseases. This sets the stage for increased research and development activities, speedy market approvals, and higher awareness through education. Additionally, current market competitors will endure pressure from the industry to continually provide advances in therapies and equipment and to compete with emerging competitors, who focus significantly on unmet needs of the ophthalmic consumer, including treatments for back of the eye conditions. The industry is likely to experience a burst of new products and heavy competition as the U.S. ophthalmic market advances.
This BCC Research report, U.S. Market for Prescription Ophthalmic Pharmaceuticals, Devices, Diagnostics and Surgical Equipment, provides a comprehensive description of conditions and diseases affecting the eye and products used for treatment. The study includes information regarding the incidence and prevalence of eye conditions and risk factors associated with those conditions. The major product segments presented with in-depth market and competitive analyses are ophthalmic prescription drugs, devices, diagnostics and surgical procedures. Research and development activities are included with an emphasis on segments offering benefits to aging populations.
SCOPE OF STUDY
This report contains:
- A thorough evaluation of the U.S. prescription ophthalmic pharmaceutical, device, diagnostic, and surgical market, with forecasts to 2011
- Market analysis focused on specific diseases and conditions such as cataract, glaucoma and refractive treatments
- Information regarding incidence and prevalence of eye conditions and risk factors associated with those conditions
- Examination of research and development activities with an emphasis on segments offering benefits to aging populations
- Profiles of the major companies in the industry as well as a detailed patent analysis.
METHODOLOGY
The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key executives, product managers, and clinical specialists involved in the ophthalmic drug industry. Secondary methods included published literature in the area of ophthalmic drugs, investment reports, company literature, and various medical and business journals.
All market data pertains the U.S. market at the manufacturers' level. Data is expressed in current U.S. dollars. The base year of the report is 2006, with historical data provided for 2004 and 2005 and forecast data provided for 2011. Historical, base year, and forecast data is provided for each market segment of the report. Competitor market shares are provided for each market segment for the 2006 base year.
ANALYST CREDENTIALS
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over-the-counter pharmaceuticals and various healthcare-related topics. Ms. Elder has worked in the healthcare field for the past 11 years and has a wide range of experience.
Report Highlights
-
The 2002 U.S. market for prescription ophthalmic drugs was $2.8 billion, and, rising at an average annual growth rate (AAGR) of 8.6%, will reach $4.5 billion in 2007.
-
Glaucoma treatments accounted for $1.4 billion in 2002 and will grow at an AAGR of 8.2% to more than $2 billion in 2007.
-
Products within the ocular infection and ocular allergy treatment segments follow in market presence, with $500 million and $397.1 million, respectively.
-
Ocular allergy treatment will lead growth with an AAGR of 10% through the period, reaching nearly $640 million
Related Reports
Recent Reports
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
ESG Trends in Chemical Industry
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Smartphone-Based Patient Monitoring: Global Market
The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.
Non-Fungible Tokens (NFT): Global Market
The global NFTs market should reach $37.6 billion by 2022 and $125.6 billion by 2027, with a compound annual growth rate (CAGR) of 27.3% during the forecast period of 2022-2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More